Related Experiment Video
Updated: May 22, 2026
09:33
Preparation Of Neovascular Tissues from Human Glioma Tissues for Quantitative Proteomics Analysis of Tumor Angiogenesis
Published on: March 20, 2026
Selective blockade of tumor angiogenesis
Amit Chaudhary1, Brad St Croix
1Tumor Angiogenesis Section, Mouse Cancer Genetics Program, National Cancer Institute, National Institutes of Health, Frederick, MD, USA.
Cell Cycle (Georgetown, Tex.)
|May 24, 2012
Summary
Targeting Tumor Endothelial Marker 8 (TEM8) with antibodies shows promise for blocking tumor angiogenesis and growth. This approach offers a new strategy for cancer therapy with no detectable toxicity.
Area of Science:
- Oncology
- Molecular Biology
- Biochemistry
Background:
- Tumor angiogenesis is crucial for cancer growth, but current therapies have limitations.
- Tumor Endothelial Marker 8 (TEM8) is a cell surface receptor overexpressed in tumor vasculature.
- TEM8 is implicated in promoting tumor angiogenesis and growth.
Purpose of the Study:
- To investigate TEM8 as a therapeutic target for blocking tumor angiogenesis.
- To evaluate the efficacy and safety of anti-TEM8 antibodies in preclinical cancer models.
Main Methods:
- Genetic disruption of Tem8 in mice to assess its role in tumor development.
- Preclinical studies using antibodies targeting the extracellular domain of TEM8.
- Assessment of anti-TEM8 antibody effects on tumor angiogenesis and xenograft growth.
Main Results:
- Genetic disruption of Tem8 inhibited tumor growth without affecting normal development.
- Antibodies targeting TEM8 effectively inhibited tumor angiogenesis and xenograft growth.
- Anti-TEM8 antibodies enhanced the efficacy of other cancer treatments and showed no toxicity.
Conclusions:
- TEM8 is a critical regulator of tumor angiogenesis and a viable therapeutic target.
- Anti-TEM8 antibodies represent a promising new strategy for cancer treatment.
- This approach may also be applicable to other angiogenesis-dependent diseases.
More Related Videos
08:19Transfer of Manipulated Tumor-associated Neutrophils into Tumor-Bearing Mice to Study their Angiogenic Potential In Vivo
Published on: July 20, 2019
09:03Monitoring Functionality and Morphology of Vasculature Recruited by Factors Secreted by Fast-growing Tumor-generating Cells
Published on: November 23, 2014
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
01:24Regulation of Angiogenesis and Blood Supply
Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits. Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl hydroxylase and factor...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
01:10Mechanism of Angiogenesis
Blood vessel formation starts early during embryonic development, around day 7. In the extraembryonic yolk sac, mesodermal precursor cells called hemangioblast proliferate and differentiate into angioblast. Angioblasts express vascular endothelial growth factor receptor 2 or VEGFR2, which binds VEGF-A, a proangiogenic factor, guiding blood vessel formation. VEGF signaling promotes angioblasts to form a blood island in the developing embryo. Angioblasts further differentiate, giving rise to...
02:34Inhibition of Cdk Activity
The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
02:38Mitogens and the Cell Cycle
Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...